Translational Development Acquisition 3Q 2026: Net loss ($9.29M) — 10-Q Summary
Translational Development Acquisition reported a net loss of $9.29M for 3Q 2026, compared to a profit of $1.66M a year earlier. The loss was driven by a $11.0M loss on a Subscription Agreement and $548K in administrative costs, partly offset by $800K in fair-value changes and $1.5M in trust-account dividends. The company has no operating revenues. It plans to merge with ProLogium and extended its business combination deadline to November 24, 2026.
